Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Surmodics Inc (SRDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 702,547
  • Shares Outstanding, K 13,482
  • Annual Sales, $ 81,340 K
  • Annual Income, $ -4,460 K
  • 60-Month Beta 1.32
  • Price/Sales 8.71
  • Price/Cash Flow 53.31
  • Price/Book 6.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.00
  • Number of Estimates 1
  • High Estimate 0.00
  • Low Estimate 0.00
  • Prior Year 0.07
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.94 +1.32%
on 03/18/19
61.08 -22.13%
on 02/21/19
-9.25 (-16.28%)
since 02/15/19
3-Month
44.70 +6.40%
on 12/27/18
61.08 -22.13%
on 02/21/19
-5.52 (-10.40%)
since 12/18/18
52-Week
34.06 +39.66%
on 04/30/18
82.35 -42.25%
on 09/04/18
+10.31 (+27.68%)
since 03/16/18

Most Recent Stories

More News
Here's Why You Should Buy Masimo (MASI) Stock Right Now

Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.

VIVO : 16.36 (-0.85%)
SRDX : 47.56 (-8.73%)
MASI : 132.26 (-0.93%)
BIO : 313.67 (+1.08%)
BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost

Becton, Dickinson (BDX) receives a number of regulatory approvals of late.

VIVO : 16.36 (-0.85%)
SRDX : 47.56 (-8.73%)
BDX : 244.67 (-3.64%)
BIO : 313.67 (+1.08%)
Here's Why You Should Invest in Stryker (SYK) Stock Right Now

Stryker (SYK) makes a few lucrative acquisitions in recent times.

VIVO : 16.36 (-0.85%)
SYK : 193.58 (-0.24%)
SRDX : 47.56 (-8.73%)
BIO : 313.67 (+1.08%)
Here's Why You Should Hold Becton, Dickinson Stock for Now

Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.

MMSI : 60.19 (-1.15%)
SRDX : 47.56 (-8.73%)
BDX : 244.67 (-3.64%)
CAH : 49.97 (-0.60%)
DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors

DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.

MMSI : 60.19 (-1.15%)
ABT : 78.83 (-1.29%)
SRDX : 47.56 (-8.73%)
XRAY : 49.51 (+0.86%)
Here's Why You Should Buy Varian Medical (VAR) Stock Now

Buoyed by a strong first quarter, Varian Medical (VAR) has kept its fiscal 2019 guidance intact.

MMSI : 60.19 (-1.15%)
ABT : 78.83 (-1.29%)
SRDX : 47.56 (-8.73%)
VAR : 135.57 (-0.75%)
Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates

Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.

MMSI : 60.19 (-1.15%)
ABT : 78.83 (-1.29%)
SRDX : 47.56 (-8.73%)
CSII : 39.46 (-0.58%)
Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues

Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.

ABT : 78.83 (-1.29%)
SRDX : 47.56 (-8.73%)
VEEV : 122.45 (+0.07%)
CSII : 39.46 (-0.58%)
Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates

Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.

WMGI : 32.16 (-0.53%)
ABT : 78.83 (-1.29%)
SRDX : 47.56 (-8.73%)
CSII : 39.46 (-0.58%)
Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts

Bruker's (BRKR) CALID and NANO groups hold promise.

ABT : 78.83 (-1.29%)
SRDX : 47.56 (-8.73%)
BRKR : 39.26 (+1.00%)
CSII : 39.46 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SRDX with:

Business Summary

SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring...

See More

Key Turning Points

2nd Resistance Point 54.03
1st Resistance Point 50.79
Last Price 47.56
1st Support Level 45.63
2nd Support Level 43.71

See More

52-Week High 82.35
Fibonacci 61.8% 63.90
Fibonacci 50% 58.20
Fibonacci 38.2% 52.50
Last Price 47.56
52-Week Low 34.06

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar